Recruitment Status

Not yet recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3253

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Schizophrenia Prodromal, SCHIZOPHRENIA 1 (Disorder), Psychosis
Interventions: Online Motivation Enhancing Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: SEPA+PrEP Women; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Interventions: Busulfan, Melphalan, Fludarabine, CD34+ Allogeneic Peripheral Blood Stem Cell Transplant; Drug · Procedure
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Huntington Disease
Interventions: Not listed
Lead sponsor: BioSensics; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 2
States / cities: Rochester, New York • Nashville, Tennessee

Conditions: Consciousness, Level Altered
Interventions: Low-intensity focused ultrasound pulsation (LIFUP), Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy, Multi-modal glymphatic function MRI; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Nodal Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Mosunetuzumab, Polatuzumab Vedotin, Positron Emission Tomography, Survey Administration, Zanubrutinib; Procedure · Biological · Drug + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 14
States / cities: Newark, Delaware • Coeur d'Alene, Idaho • Post Falls, Idaho + 10 more

Conditions: Skin Substitutes, Secondary Intention Healing, Skin Cancer Healing
Interventions: Skin Substitute, Secondary Intention Healing; Biological
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder
Interventions: Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia; Behavioral · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease
Interventions: Busulfan, Melphalan, Fludarabine, CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC); Drug · Device
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 72 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2034
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension
Interventions: Self-Titration; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 35 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Early-Stage Non-Small Cell Lung Cancer
Interventions: Pumitamig, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more

Not yet recruiting clinical trials

Filter and sort this status page

Live official records

Online Intervention To Improve Motivation

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

SEPA+PrEP-Women Pilot Trial for HIV Prevention Among Women at Risk for HIV

CD34+ Transplants for Myeloid Malignancies

Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease

Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation

Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment

Skin Subs vs Secondary Intention

Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Antihypertensive Self-titration in US Primary Care

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)